Intensive Care and Perioperative Management of Neonates With Functionally Univentricular Hearts

The Heart Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA.
World Journal for Pediatric and Congenital Hearth Surgery 07/2012; 3(3):359-363. DOI: 10.1177/2150135111433473
Source: PubMed


Although mortality rates for patients with univentricular hearts continue to fall, the course in the intensive care unit is remarkable for significant morbidity and utilization of significant resources. Preoperative patient management focuses on balancing competing circulations, pulmonary and systemic, which exist in parallel rather than in series, as in the normal circulation. Postoperative patient management focuses on optimizing systemic output, respiratory status, and mitigating the effects of cardiopulmonary bypass. In this article, we review pre- and postoperative intensive care management in neonates with a univentricular heart.

1 Follower
10 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Every year in the United States approximately 40,000 infants are born with congenital heart disease. Several of these infants require corrective or palliative surgery in the neonatal period. Mortality rates after cardiac surgery are highest amongst neonates, particularly those born prematurely. There are several reasons for the increased surgical mortality risk in neonates. This review outlines these risks, with particular emphasis on the relative immaturity of the organ systems in the term and preterm neonate.
    Pediatric Cardiac Surgery Annual of the Seminars in Thoracic and Cardiovascular Surgery 04/2013; 16(1):21-31. DOI:10.1053/j.pcsu.2013.01.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: La vía univentricular es necesaria en cualquier anomalía congénita en la que no sea posible realizar una reparación biventricular con éxito. En el siguiente manuscrito describiremos los 3 estadios de paliación univentricular, es decir, la paliación neonatal, Glenn y Fontan y enfatizaremos especialmente sobre el momento de su realización y las complicaciones, así como sobre las indicaciones y las contraindicaciones.
    Cirugia Cardiovascular 04/2014; 21(2). DOI:10.1016/j.circv.2014.03.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the advancement in the post-operative care of neonates with congenital heart disease (CHD), there is little information on preoperative management of systemic and regional hemodynamics, which may be related to outcomes. We aimed to determine the preoperative effect of milrinone, a phosphodiesterase III inhibitor, on cardiac output, splanchnic and cerebral perfusion in neonates with CHD. Neonates with CHD requiring cardiac surgery were enrolled in a prospective, single-blinded study once a clinical decision of starting milrinone (0.75 mcg/kg/min IV) using institutional criteria was made. Demographic and clinical variables and outcomes were recorded. Combined cardiac output and measures of splanchnic (superior mesenteric (SMA) and celiac arteries) and cerebral (anterior and middle cerebral arteries) perfusion were determined by Doppler studies at 0, 6, 24 and 48h after milrinone infusion. Investigators were unaware of intervention time points and patients in analyzing blood flow measurements. 17 term (39.2±1.3 weeks) neonates were included with hypoplastic left heart syndrome (78.5%) as the most common diagnosis. Combined cardiac output increased by 28% within 48h (613±154 vs. 479±147 ml/kg/min at baseline, p<0.05). SMA mean velocity increased at 6h and throughout 48 h of milrinone infusion (p<0.05). Peak and mean velocities at cerebral arteries increased with milrinone infusion (p<0.05∼0.08) and the corresponding changes at celiac artery were modest. There were no significant changes in splanchnic and cerebral resistive and pulsatility indices during milrinone infusion. Milrinone increases cardiac output with concurrent effects on splanchnic and cerebral blood flows during the short-term preoperative use in neonates with CHD.
    Shock (Augusta, Ga.) 04/2015; Publish Ahead of Print(2). DOI:10.1097/SHK.0000000000000388 · 3.05 Impact Factor